Cedrik M. Britten

7.7k citations

72 papers · 3.6k indexed · 1 hit paper · h-index 30

Immunology top 0.5%
Oncology top 2%
Molecular Biology top 5%
Genetics top 10%
Epidemiology top 10%

Co-authors: Uğur Şahin Sebastian Kreiter Özlem Türeci Mustafa Diken Sylvia Janetzki Christoph Huber Sjoerd H. van der Burg Marij J.P. Welters
Topics: Immunotherapy and Immune Responses (40 papers)Immune Cell Function and Interaction (22 papers)CAR-T cell therapy research (20 papers)
Cited by: Immunology Oncology Molecular Biology
Journals: Journal of Clinical OncologySHILAP Revista de lepidopterologíaBlood
Partner nations: Germany Netherlands United States

In The Last Decade

Cedrik M. Britten

71 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Exploiting the Mutanome for Tumor Vaccination

2012 617 citations John C. Castle, Sebastian Kreiter et al. Cancer Research profile →

Peers

Countries citing papers authored by Cedrik M. Britten

Since Specialization

Citations

This map shows the geographic impact of Cedrik M. Britten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cedrik M. Britten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cedrik M. Britten more than expected).

Fields of papers citing papers by Cedrik M. Britten

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cedrik M. Britten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cedrik M. Britten. The network helps show where Cedrik M. Britten may publish in the future.

Co-authorship network of co-authors of Cedrik M. Britten

This figure shows the co-authorship network connecting the top 25 collaborators of Cedrik M. Britten. A scholar is included among the top collaborators of Cedrik M. Britten based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cedrik M. Britten. Cedrik M. Britten is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1600O Efficacy and safety of IMA203, a PRAME-directed T-cell receptor (TCR) T-cell therapy, in patients with previously treated advanced or metastatic uveal melanoma from a phase I trial 2025 ·Annals of Oncology ·Sapna P. Patel,Apostolia M. Tsimberidou,Jason J. Luke,Winfried Alsdorf,Antonia Busse,(unknown),(unknown),Norbert Hilf,M. Alper Kursunel,Andrea Mayer-Mokler,Dmitry Pankov,Cedrik M. Britten,Martin Wermke,Leonel F. Hernandez‐Aya	0
2	Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study 2016 ·Cancer Immunology Immunotherapy ·Susanna Mandruzzato,Sven Brandau,Cedrik M. Britten,Vincenzo Bronte,Vera Damuzzo,Cécile Gouttefangeas,Dominik Maurer,Christian H. Ottensmeier,Sjoerd H. van der Burg,Marij J.P. Welters,Steffen Walter	169
3	Functional TCR Retrieval from Single Antigen-Specific Human T Cells Reveals Multiple Novel Epitopes 2014 ·Cancer Immunology Research ·Petra Simon,Tana Omokoko,Andrea Breitkreuz,(unknown),Sebastian Kreiter,Sebastian Attig,Abdo Konur,Cedrik M. Britten,Claudia Paret,Karl Dhaene,Özlem Türeci,Uğur Şahin	32
4	Efficient Induction of Antitumor Immunity by Synthetic Toll-like Receptor Ligand–Peptide Conjugates 2014 ·Cancer Immunology Research ·Gijs G. Zom,Selina Khan,Cedrik M. Britten,(unknown),Marcel Camps,Nikki M. Loof,(unknown),Nico J. Meeuwenoord,Dmitri V. Filippov,Gijsbert A. van der Marel,Herman S. Overkleeft,Cornelis J.M. Melief,Ferry Ossendorp	81
5	Phenotyping of peripheral blood mononuclear cells of patients with advanced heavily pre-treated adenocarcinoma of the stomach and gastro-esophageal junction 2014 ·Cancer Immunology Immunotherapy ·(unknown),Sebastian Attig,Cedrik M. Britten,Henning Schulze‐Bergkamen,Florian Lordick,Goetz von Wichert,Peter Thuss‐Patience,Alexander Stein,Martin Schüler,Florian Bassermann,Uğur Şahin,Özlem Türeci	1
6	Exploiting the Mutanome for Tumor Vaccinationbreakdown → 2012 ·Cancer Research ·John C. Castle,Sebastian Kreiter,Jan Diekmann,Martin Löwer,Niels van de Roemer,Jos de Graaf,Abderraouf Selmi,Mustafa Diken,Sebastian Boegel,Claudia Paret,Michael Koslowski,Andreas N. Kuhn,Cedrik M. Britten,Christoph Huber,Özlem Türeci,Uğur Şahin	617
7	Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols 2012 ·Cancer Immunology Immunotherapy ·(unknown),Sebastian Attig,Nicole Bidmon,Bernhard Y. Renard,Sylvia Janetzki,Uğur Şahin,Marij J.P. Welters,Christian H. Ottensmeier,Sjoerd H. van der Burg,Cécile Gouttefangeas,Cedrik M. Britten	20
8	Advancing the field of cancer immunotherapy 2012 ·OncoImmunology ·Axel Hoos,Sylvia Janetzki,Cedrik M. Britten	4
9	Harmonization of the intracellular cytokine staining assay 2012 ·Cancer Immunology Immunotherapy ·Marij J.P. Welters,Cécile Gouttefangeas,Tamara H. Ramwadhdoebé,Anne Letsch,Christian H. Ottensmeier,Cedrik M. Britten,Sjoerd H. van der Burg	32
10	Response Determination Criteria for ELISPOT: Toward a Standard that Can Be Applied Across Laboratories 2011 ·Methods in molecular biology ·Zoe Moodie,Leah Price,Sylvia Janetzki,Cedrik M. Britten	42
11	Intranodal Vaccination with Naked Antigen-Encoding RNA Elicits Potent Prophylactic and Therapeutic Antitumoral Immunity 2010 ·Cancer Research ·Sebastian Kreiter,Abderraouf Selmi,Mustafa Diken,Michael Koslowski,Cedrik M. Britten,Christoph Huber,Özlem Türeci,Uğur Şahin	248
12	Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond 2010 ·Cancer Immunology Immunotherapy ·Cedrik M. Britten,Sylvia Janetzki,Sjoerd H. van der Burg,Christoph Huber,Michael Kalos,(unknown),Holden T. Maecker,Cornelis J.M. Melief,Jill O’Donnell-Tormey,Kunle Odunsi,Lloyd J. Old,Graham Pawelec,Bart O. Roep,Pedro Romero,Axel Hoos,Mark M. Davis	38
13	CIMT 2010: Report on the eighth annual meeting of the association for cancer immunotherapy, May 26–28, 2010, Mainz, Germany 2010 ·Cancer Immunology Immunotherapy ·Satwinder Singh,(unknown),Cécile Gouttefangeas,Cedrik M. Britten,Marij J.P. Welters	2
14	Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium 2009 ·Cancer Immunology Immunotherapy ·(unknown),Cedrik M. Britten,Sylvia Janetzki,Leah Ben‐Porat,Timothy M. Clay,Michael Kalos,Holden T. Maecker,Kunle Odunsi,Michael W. Pride,Lloyd J. Old,Axel Hoos,Pedro Romero	47
15	Performance of serum-supplemented and serum-free media in IFNγ Elispot Assays for human T cells 2009 ·Cancer Immunology Immunotherapy ·Sylvia Janetzki,Leah Price,Cedrik M. Britten,Sjoerd H. van der Burg,(unknown),Jeffrey R. Currier,Guido Ferrari,Cécile Gouttefangeas,Peter Hayes,Eckhart Kaempgen,Volker Lennerz,(unknown),Victor Costa de Souza,Axel Hoos	44
16	Chirality of TLR-2 ligand Pam3CysSK4 in fully synthetic peptide conjugates critically influences the induction of specific CD8+ T-cells 2008 ·Molecular Immunology ·Selina Khan,Jimmy J. Weterings,Cedrik M. Britten,(unknown),(unknown),Cornelis J.M. Melief,Sjoerd H. van der Burg,Gijs van der Marel,Herman S. Overkleeft,Dmitri V. Filippov,Ferry Ossendorp	54
17	Rapid identification of an HLA-B1501-restricted vaccinia peptide antigen 2007 ·Vaccine* ·Ralf G. Meyer,Claudine Graf,Cedrik M. Britten,Christoph Huber,Thomas Wölfel	3
18	Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI) 2007 ·Cancer Immunology Immunotherapy ·Sylvia Janetzki,Katherine S. Panageas,Leah Ben‐Porat,Jean Boyer,Cedrik M. Britten,Timothy M. Clay,Michael Kalos,Holden T. Maecker,Pedro Romero,Jianda Yuan,W. Martin Kast,Axel Hoos,(unknown)	150
19	Cancer Immunotherapy 2005: Mainz, Germany, 12–13 May 2005 2005 ·Cancer Immunology Immunotherapy ·Cedrik M. Britten,Cécile Gouttefangeas,Sebastian Kreiter	1
20	Immunologic Analysis of a Phase I/II Study of Vaccination with MAGE-3 Protein Combined with the AS02B Adjuvant in Patients with MAGE-3-Positive Tumors 2004 ·Journal of Immunotherapy ·Valérie Vantomme,(unknown),(unknown),(unknown),Dirk Gheysen,Claudine Bruck,G. Stoter,Cedrik M. Britten,Ulrich Keilholz,C. B. H. W. Lamers,Marie Marchand,M Delire,(unknown)	70

About Cedrik M. Britten

Cedrik M. Britten is a scholar working on Immunology, Oncology and Hematology, having authored 72 papers that have together received 3.6k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (40 papers), Immune Cell Function and Interaction (22 papers) and CAR-T cell therapy research (20 papers). The work is most often cited by research in Immunology (2.7k citations), Oncology (1.6k citations) and Molecular Biology (1.5k citations). Cedrik M. Britten has collaborated with scholars based in Germany, Netherlands and United States. Frequent co-authors include Uğur Şahin, Sebastian Kreiter, Özlem Türeci, Mustafa Diken, Sylvia Janetzki, Christoph Huber, Sjoerd H. van der Burg, Marij J.P. Welters, Michael Koslowski and Cécile Gouttefangeas. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact